Holen Sie sich die Stockscreener-App
1.45
0.68%
-0.01
Schlusskurs vom Vortag:
$1.46
Offen:
$1.43
24-Stunden-Volumen:
357.10K
Relative Volume:
0.35
Marktkapitalisierung:
$115.43M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
29.00
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
-3.97%
1M Leistung:
-2.03%
6M Leistung:
-40.33%
1J Leistung:
+36.79%
1-Tages-Spanne:
$1.4104
$1.475
1-Wochen-Bereich:
$1.4104
$1.53
52-Wochen-Spanne:
$0.8214
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.45 | 116.23M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix BioTherapeutics Inc. stock momentum explainedWatchlist Summary for Active Day Traders - Newser
Why Protalix BioTherapeutics Inc. stock attracts strong analyst attentionDaily Pattern Analysis with Return Forecast - Newser
Key metrics from Protalix BioTherapeutics Inc.’s quarterly dataReal-Time Equity Price Action Analysis - Newser
Protalix Lawsuit Dismissed After Bylaws Amendment - TipRanks
What is Protalix BioTherapeutics Inc. company’s growth strategyBeginner Investor Data Feed For Every Investor - jammulinksnews.com
What are the latest earnings results for Protalix BioTherapeutics Inc.Breakout Stocks Ideas For 2025 - jammulinksnews.com
Advanced analytics toolkit walkthrough for Protalix BioTherapeutics Inc.Investment Roadmap for High Potential Stocks - Newser
What makes Protalix BioTherapeutics Inc. stock price move sharplyFree Stock Selection With High Accuracy - Newser
How institutional ownership impacts Protalix BioTherapeutics Inc. stockSecure Buy Strategy Based on Risk Parameters - Newser
How Protalix BioTherapeutics Inc. stock reacts to Fed policy changesPredictive Screener for Daily Trade Watch - Newser
Is Protalix BioTherapeutics Inc. a Top Dividend Stock to Watch in 2025Entry Zone Watchlist With Momentum Focus - Newser
Plant Derived Proteins Market Driven by Protalix to Novo Nordisk, Poised for Robust Expansion - FMIBlog
Protalix BioTherapeutics Inc. At Decision Level — Rebound or ResistanceWeekly Stock Watch With Growth Focus Expanded - beatles.ru
Is Protalix BioTherapeutics Inc. Forming a Consolidation BaseShort Term Setup With Predictive Chart Confirmed - metal.it
Key External Factors That Drive Protalix BioTherapeutics Inc. Stock Price MovementsGrowth Projection Summary for Long-Term Investors - Newser
Published on: 2025-07-29 01:26:29 - metal.it
Is Protalix BioTherapeutics Inc. stock overvalued or undervaluedCapitalize on fast-moving stock opportunities - jammulinksnews.com
Published on: 2025-07-27 22:47:19 - jammulinksnews.com
When is Protalix BioTherapeutics Inc. stock expected to show significant growthTremendous return rates - jammulinksnews.com
What analysts say about Protalix BioTherapeutics Inc. stockUnprecedented profit potential - PrintWeekIndia
What drives Protalix BioTherapeutics Inc. stock priceHigh-yield trading alerts - Autocar Professional
What makes Protalix BioTherapeutics Inc. stock attractive to long term investorsFree Predictions - jammulinksnews.com
How Protalix BioTherapeutics Inc. stock performs during market volatilityTrend Based Entry Alerts - Newser
Is Protalix BioTherapeutics Inc. a good long term investmentFree Wealth Management Insights - Autocar Professional
Protalix BioTherapeutics Inc. Stock Analysis and ForecastMassive wealth growth - Autocar Professional
Protalix Appoints New CFO to Boost Growth Strategy - The Globe and Mail
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):